Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C - PubMed (original) (raw)
Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C
Marek Radkowski et al. Hepatology. 2005 Jan.
Abstract
It is unclear whether the current antiviral treatment for chronic hepatitis C virus (HCV) infection results in complete elimination of the virus, or whether small quantities of virus persist. Our study group comprised 17 patients with chronic HCV who had sustained virological response (SVR) after interferon/ribavirin treatment. Serum and peripheral blood mononudear cells were collected 2 to 3 times at 3- to 6-month intervals starting 40 to 109 months (mean, 64.2 +/- 18.5 months) after the end of therapy. In addition, lymphocyte and macrophage cultures were established at each point. In 11 patients, frozen liver tissue samples were available from follow-up biopsies performed 41 to 98 months (mean, 63.6 +/- 16.7 months) after therapy. Presence of HCV RNA was determined by sensitive reverse-transcriptase polymerase chain reaction, and concentration of positive and negative strands was determined by a novel quantitative real-time reverse transcriptase polymerase chain reaction. Only 2 of 17 patients remained consistently HCV RNA negative in all analyzed compartments. HCV RNA was detected in macrophages from 11 patients (65%) and in lymphocytes from 7 patients (41%). Viral sequences were also detected in 3 of 11 livers and in sera from 4 patients. Viral replicative forms were found in lymphocytes from 2 and in macrophages from 4 patients. In conclusion, our results suggest that in patients with SVR after therapy, small quantities of HCV RNA may persist in liver or macrophages and lymphocytes for up to 9 years. This continuous viral presence could result in persistence of humoral and cellular immunity for many years after therapy and could present a potential risk for infection reactivation.
Comment in
- HCV persistence: cure is still a four letter word.
Feld JJ, Liang TJ. Feld JJ, et al. Hepatology. 2005 Jan;41(1):23-5. doi: 10.1002/hep.20561. Hepatology. 2005. PMID: 15690477 Review. No abstract available. - Occult viral hepatitis: what is the significance?
Blendis L. Blendis L. Gastroenterology. 2005 Jun;128(7):2168-70. doi: 10.1053/j.gastro.2005.02.070. Gastroenterology. 2005. PMID: 15940651 No abstract available.
Similar articles
- Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N. Sharma RK, et al. Clin Transplant. 2006 Nov-Dec;20(6):677-83. doi: 10.1111/j.1399-0012.2006.00534.x. Clin Transplant. 2006. PMID: 17100715 - Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
Januszkiewicz-Lewandowska D, Wysocki J, Pernak M, Nowicka K, Zawada M, Rembowska J, Lewandowski K, Mańkowski P, Nowak J. Januszkiewicz-Lewandowska D, et al. Jpn J Infect Dis. 2007 Feb;60(1):29-32. Jpn J Infect Dis. 2007. PMID: 17314422 - Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS, Morsica G, Chen CH, Mele L, Baccarini P, Chianese R, Piccinini A, Lazzarin A, Pisi E. De Mitri MS, et al. Ital J Gastroenterol Hepatol. 1997 Jun;29(3):255-61. Ital J Gastroenterol Hepatol. 1997. PMID: 9646218 - Hepatitis C virus infection: an overview.
Hwang SJ. Hwang SJ. J Microbiol Immunol Infect. 2001 Dec;34(4):227-34. J Microbiol Immunol Infect. 2001. PMID: 11825001 Review. - [Treatment of patients with chronic hepatitis C virus infection and normal transaminases].
Serfaty L. Serfaty L. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B202-5. Gastroenterol Clin Biol. 2002. PMID: 12180289 Review. French. No abstract available.
Cited by
- Monocyte and Macrophage Functions in Oncogenic Viral Infections.
Echevarria-Lima J, Moles R. Echevarria-Lima J, et al. Viruses. 2024 Oct 15;16(10):1612. doi: 10.3390/v16101612. Viruses. 2024. PMID: 39459945 Free PMC article. Review. - Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses.
Su CM, Du Y, Rowland RRR, Wang Q, Yoo D. Su CM, et al. Front Immunol. 2023 Apr 17;14:1172000. doi: 10.3389/fimmu.2023.1172000. eCollection 2023. Front Immunol. 2023. PMID: 37138878 Free PMC article. Review. - Global prevalence of occult hepatitis C virus: A systematic review and meta-analysis.
Mbaga DS, Kenmoe S, Bikoï JN, Takuissu GR, Amougou-Atsama M, Okobalemba EA, Ebogo-Belobo JT, Bowo-Ngandji A, Oyono MG, Magoudjou-Pekam JN, Kame-Ngasse GI, Nka AD, Feudjio AF, Zemnou-Tepap C, Velhima EA, Ondigui JLN, Nayang-Mundo RA, Touangnou-Chamda SA, Takeu YK, Taya-Fokou JB, Mikangue CAM, Kenfack-Momo R, Kengne-Ndé C, Sake CS, Esemu SN, Njouom R, Ndip L, Essama SHR. Mbaga DS, et al. World J Methodol. 2022 May 20;12(3):179-190. doi: 10.5662/wjm.v12.i3.179. eCollection 2022 May 20. World J Methodol. 2022. PMID: 35721241 Free PMC article. - Benign course of residual inflammation at end of treatment of liver transplant recipients after sofosbuvir based therapy.
Ismail B, Benrajab KM, Bejarano P, Ruiz P, Sears D, Tzakis A, Zervos XB. Ismail B, et al. World J Hepatol. 2022 Mar 27;14(3):602-611. doi: 10.4254/wjh.v14.i3.602. World J Hepatol. 2022. PMID: 35582292 Free PMC article. - Adaptive MHC-E restricted tissue-resident NK cells are associated with persistent low antigen load in alveolar macrophages after SARS-CoV-2 infection.
Huot N, Planchais C, Contreras V, Jacquelin B, Petitdemange C, Lazzerini M, Rosenbaum P, Rey F, Reeves RK, Le Grand R, Mouquet H, Müller-Trutwin M. Huot N, et al. Res Sq [Preprint]. 2022 Apr 25:rs.3.rs-1561222. doi: 10.21203/rs.3.rs-1561222/v1. Res Sq. 2022. PMID: 35547853 Free PMC article. Updated. Preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources